Sourced cannabinoid profiles: researched benefits, risks, personal accounts and documented forms. Explore the evidence and the questions that remain open.
This index covers compounds of editorial interest and a selection of emerging molecules. It is not a census of every possible cannabinoid or a claim that all have clinical evidence. Ambiguous commercial names are identified in their entries.
38 entries
The number in 10-OH-HHC indicates a chemical position, not a superior generation of HHC. Identity documentation exists, but a commercial name alone does not establish composition, benefits or a known profile of human effects.
Identity / very sparse data
2-AG offers a way to explore returning messages between neurons. Here we follow questions that help interpret them, without turning an interesting physiological explanation into advice for changing the body.
Laboratory or animals
9-OH-HHC appears in research on chemical identity and sample composition. It is a particularly useful example of why an analytical finding does not demonstrate a therapeutic application, and why a structure’s small details matter.
Identity / very sparse data
Anandamide changes the perspective: understanding cannabinoids also means looking at signals produced within the body. Its story connects chemical identification, receptors and mechanisms that end a signal; it is not a simple explanation for all human happiness.
Laboratory or animals
CBC appears in research on receptors, inflammation and seizures in animals. These are different scientific clues, not a collection of benefits demonstrated in people. Its interest lies precisely in testing which signals survive the move from one model to another.
Laboratory or animals
CBCA has a documented chemical identity and laboratory signals worth following. Antibacterial research is striking, but does not show that a CBCA product treats infections. A culture plate and a patient present different problems.
Laboratory or animals
CBCV offers two useful lessons in reading science: appearing in an experiment does not mean sharing all its results, and a simulation is not a therapy. Both distinctions matter particularly when a headline groups several molecules under one promise.
Laboratory or animals
CBD has clinical evidence for specific indications, but its name also appears in much broader promises. The key is distinguishing a studied medicine from any preparation sharing the molecule, and a personal experience from a result compared with placebo.
Clinical · specific indications
CBDA is the acidic form related to CBD, but does not automatically inherit its medical evidence. Research includes animal models of nausea and experiments on cellular channels. These are specific clues best kept with their limits, without making “precursor” synonymous with better.
Laboratory or animals
Getting to know CBDB involves two separate questions: how to recognise its identity, and which evidence describes its effects. The distinction helps us read a composition report without turning every new name into a medical application that still requires proof.
Laboratory or animals
CBDH offers a useful introduction to the work of identifying similar molecules. Its interest begins before any possible application: understanding which analytical signal belongs to which structure, and how much can actually be claimed from that identification.
Laboratory or animals
Understanding CBDP means separating three questions: what the molecule is, what it does in an experiment, and what has been demonstrated in people. That distinction lets us appreciate recent research without turning a chemical discovery into a promise of better health.
Laboratory or animals
CBDV has human trials, but their existence does not mean a favourable outcome. Two studies of focal seizures and neuropathic pain did not demonstrate an advantage over placebo on their primary outcomes. It illustrates why investigating and confirming are different verbs.
Early human studies
CBE’s story crosses three settings: chemical changes in a formulation, animal metabolism and receptor assays. Following those settings separately prevents confusion between what appears in a sample and what a product would do in a person.
Laboratory or animals
CBG has begun moving from surveys and laboratories into human trials. Findings do not all point in the same direction: an acute anxiety signal does not establish treatment of a disorder, and the sleep trial did not confirm its primary objective.
Early human studies
CBGA occupies an important point in the plant’s chemistry, but being a precursor does not make it a superior treatment. Its animal epilepsy research includes opposite findings depending on the model: retaining that contradiction is essential to explaining what is known.
Laboratory or animals
CBGV is a distinct molecule, not another name for CBG. The reviewed evidence combines analytical identification and cellular experiments. Sparse human data limit what can be said about benefits and risks; they are not an invitation to fill gaps with analogy.
Laboratory or animals
A scientific profile needs to revisit its sources rather than simply repeat old conclusions. For CBL, the useful question is what each experiment supports and where interpretation begins. Keeping that boundary visible makes reading both more interesting and more precise.
Laboratory or animals
CBN and sleep often appear together, but trials require a more careful headline. Some secondary measures improve; the primary outcomes of two studies did not reach significance. The interesting question is what was measured, not how often “for sleep” is repeated.
Early human studies
Before assigning properties to CBT, establish which full name the letters stand for. This profile starts with cannabitriol; it also explains why a search may return cannabicitran, a different molecule whose findings must not be mixed with those for cannabitriol.
Laboratory or animals
H4CBD resembles CBD in name, but needs its own evidence profile. Available studies describe its structure, cellular signals and metabolites. None of those findings authorises automatically transferring medical uses investigated for cannabidiol to H4CBD.
Laboratory or animals
HHC connects chemistry known for decades with a more recent market. Its different spatial forms, reported poisonings and user accounts explain why a label calling it an ‘alternative to THC’ tells us considerably less than it appears to.
Mixed evidence by question
The O in HHC-O denotes an acetate, not a version with enhanced benefits. Available evidence focuses on cellular assays, metabolism and chemical emissions; each type of study answers a different question.
Laboratory or animals
HHCH belongs to the HHC analogue family, but substance-specific data remain scarce. Forensic identification, metabolism research and published poisoning cases exist. These help frame relevant questions, not assign benefits or a precise human potency.
Mixed evidence by question
HHCP is a chemical identity distinct from HHC, not an alternative name for the same substance. Research combines sample analysis, receptor activity and clinical cases; it does not yet establish a therapeutic profile or a reliable comparison of human effects.
Mixed evidence by question
HHCP-O adds another modification to the HHCP family. Identification and metabolism data exist, but there is no clinical basis for promising benefits, specifying effect duration or ranking this substance by human potency.
Laboratory or animals
A synthetic cannabinoid used as a medicine for specific indications. It illustrates the difference between a defined clinical use and broad claims about cannabis.
Clinical · specific indications
A heterogeneous family that needs its own entry. The word cannabinoid does not imply that these compounds resemble CBD in effects, composition or risk. JWH-018 and MDMB-4en-PINACA are examples, not synonyms for the entire family.
Mixed evidence by question
Here, THC refers to delta-9-THC. It combines intoxicating effects with limited medical uses: two realities best explained together. A pharmaceutical indication does not validate every product, and recognising a risk does not erase findings for specific medicines.
Clinical · specific indications
THC-O brings together two different debates: which substance a sample actually contains and what happens when it changes. Analytical studies, emissions experiments and user surveys help unpack ambiguous labels and spectacular claims lacking clinical support.
Mixed evidence by question
THCA and THC need separate rows in a chemical explanation. The acidic form has biological research of its own, while its relationship with THC matters when interpreting analyses. Neither makes a THCA label proof of efficacy, safety or legality.
Laboratory or animals
THCB shows how a molecule can be clearly identified while its clinical profile remains very incomplete. Chemical tools and biological experiments contribute different pieces of evidence: neither can, on its own, replace an evaluation in people.
Laboratory or animals
The THCH evidence record is changing: alongside chemical identification, recent work addresses metabolism and motor effects in animals. Reading it requires attention to both the experimental model and the sample tested, without inventing equivalent effects in humans.
Laboratory or animals
THCP calls for particular care when reading potency comparisons and accounts of effects. This profile brings together a chemical discovery, laboratory research and a clinical case: three kinds of evidence that answer different questions and should not be merged.
Mixed evidence by question
THCP-O has analytical documentation, but that does not turn claims about its effects into clinical facts. The first step is distinguishing the acetate from unmodified THCP and other esters that may appear under similar commercial names.
Identity / very sparse data
THCV has been studied in metabolism and brain responses to food, but that does not establish weight loss. Trials are small and their objectives matter: a favourable secondary measure does not replace the primary outcome or a complete clinical evaluation.
Early human studies
Delta-10 THC is a good example of why chemistry cannot be reduced to a ‘mild’ or ‘stimulating’ label. Its spatial forms and the assays used affect interpretation. Available evidence remains predominantly experimental.
Laboratory or animals
Delta-8 THC has more human research than many emerging cannabinoids, but ‘less potent’ does not mean ‘non-intoxicating’. Controlled trials, favourable accounts and composition problems should be read together: none tells the whole story on its own.
Early human studiesNo matching entries.